Yk-11

by Swole Labs · capsule · 90 capsules

  • On the market (NIH)
  • DSLD label 236810
  • Serving 1 capsule
  • 90 servings

Yk-11 by Swole Labs lists 0 ingredients. Its current label entered the NIH Dietary Supplement Label Database on September 25, 2020.

What is in Yk-11?

Each row as the label prints it, per serving of 1 capsule. The capsule beside an amount places it among every product in the NIH database that lists the same ingredient: the bar is the middle half of their amounts, the line in it the median, the whiskers the 10th and 90th percentiles; the green tick is the FDA Daily Value and the red dashed tick the adult upper limit (IOM).

Yk-11: Supplement Facts rows against the market (DSLD label 236810, January 2026 release)
IngredientAmount% DVAmong products listing it
Yk-114 mg

Source: NIH ODS Dietary Supplement Label Database, label 236810 (entered September 25, 2020), version 9.4.0. See the label on DSLD. Amounts are what the maker printed; DSLD does not test products. Daily Values: the FDA's Daily Value page.

Is that a lot?

Every amount on this label with a position sits within the middle 80% of the products that list the same ingredient.

The NIH database records 1 to 2 servings a day from the label's directions; its % Daily Values are for adults and children 4 or more years of age. The directions as printed are further down this page.

The Tolerable Upper Intake Level is the most of a nutrient per day, from food, water and supplements together, that is likely to pose no risk for almost all adults (Institute of Medicine, 2011). It does not apply under medical supervision. This page compares labels; it is not medical advice.

Sources: amounts from the DSLD label; Daily Values from 21 CFR 101.9(c)(8)(iv); adult upper limits from the Institute of Medicine's DRI summary tables (2011). How positions are computed.

What does the label say about taking it?

Quoted from the label as DSLD transcribed it: the maker's words, including any claim about what the product does, which the FDA has not evaluated and PlainVitamins does not endorse.

Directions
Performance training usage: This product is intended for use as an addition to any workout regimen. As a physique enhancing agent to take 1 capsule 1 to 2 times daily. Do not consume more than 2 capsules in a 24 hour period. Do not under any circumstances exceed 4 weeks of use without at least a 30 day break. During the 30 day break period we strongly suggest the use of a proper post cycle therapy product. Cycle Resurrection has been specifically formulated to meet those needs.
Warnings
Warning: Keep out of reach of children.
Do not use if pregnant or nursing.
To report any adverse event call 1-800-332-1088 Consult your doctor prior to use if you have or are at risk for prostate disease, heart disease, or any other general medical condition.
Consult your doctor prior to use if you are taking any other medications.
Do not exceed suggested dosage. Discontinue use immediately if you experience rapid heart beat, dizziness, vomiting, or other similar symptoms. Side effects may include acne, hair loss, or increased aggressiveness. All persons are advised to consult with their doctor or other medical authority before use of this or any other dietary supplement. Caution: Athletes or other persons who are subject to testing for performance enhancing drugs may test positive when using dietary supplements. All persons are advised to consult their drug testing organization prior to use of this or any other dietary supplement.
May not be suitable for persons under the age of 18 years old.

Source: label statements in DSLD label 236810.

What else is on the label?

Other ingredients: Rice Flour, Gelatin, Magnesium Stearate.

How many labels does Yk-11 have?

One label is on file, entered on September 25, 2020.

  1. Label 236810 (current) Entered September 25, 2020 · on the market · 90 capsules

Source: DSLD label entry and market events, version 9.4.0 (labels entered through September 25, 2025).

Who makes it?

The label names Swole Labs (manufacturer). All Swole Labs products.

Where next?